

**PROSPECTUS SUPPLEMENT DATED 24 FEBRUARY 2026 TO THE BASE PROSPECTUS DATED  
10 JUNE 2025**



**AstraZeneca PLC  
(incorporated with limited liability in England)**

**AstraZeneca Finance LLC  
(a Delaware corporation)**

**US\$10,000,000,000  
Euro Medium Term Note Programme  
unconditionally and irrevocably guaranteed, in the case of Notes issued by  
AstraZeneca Finance LLC, by AstraZeneca PLC**

This Prospectus Supplement (the “**Supplement**”) to the Base Prospectus dated 10 June 2025 (the “**Base Prospectus**”), which comprises a base prospectus for the purposes of Article 8 of Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (the “**UK Prospectus Regulation**”), constitutes a supplementary prospectus for the purposes of Article 23 of the UK Prospectus Regulation and is prepared in connection with the US\$10,000,000,000 Euro Medium Term Note Programme (the “**Programme**”) established by AstraZeneca PLC and AstraZeneca Finance LLC (“**AstraZeneca Finance**” and, together with AstraZeneca PLC, the “**Issuers**”), unconditionally and irrevocably guaranteed, in the case of Notes issued by AstraZeneca Finance, by AstraZeneca PLC (in such capacity, the “**Guarantor**”). Terms defined in the Base Prospectus have the same meaning when used in this Supplement. The Financial Conduct Authority, as the UK competent authority under the UK Prospectus Regulation, has approved this Supplement.

This Supplement is supplemental to, and should be read in conjunction with, the Base Prospectus issued by the Issuers and any other supplements to the Base Prospectus issued by the Issuers.

Each Issuer and the Guarantor accept(s) responsibility for the information contained in this Supplement. To the best of the knowledge of each of the Issuers and the Guarantor the information contained in this Supplement is in accordance with the facts and this Supplement makes no omission likely to affect its import.

### **Purpose of this Supplement**

The purpose of this Supplement is:

- a) to incorporate by reference certain parts of AstraZeneca PLC’s Annual Report and Form 20-F Information 2025 for the financial year ended 31 December 2025 (“**Annual Report**”); and
- b) to update the “Significant/Material Change” statement in the Base Prospectus.

### **Information incorporated by reference**

On 24 February 2026 AstraZeneca PLC published its Annual Report. A copy of the Annual Report will be filed with the Financial Conduct Authority and, by virtue of this Supplement, pages 116 to 196 of the Annual Report (the audited consolidated financial statements of AstraZeneca PLC as at and for the year ended 31 December 2025 together with the notes thereto, prepared in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards and also comply fully with International Financial Reporting Standards as issued by the International Accounting Standards Board and International Accounting Standards as adopted by the European Union, and the independent auditor’s report to the members of AstraZeneca PLC (Group), and the definition and reconciliation of constant exchange rate growth rates and core measures set out on pages 53 to 55, (available at:

<https://www.astrazeneca.com/investor-relations/annual-reports.html>), is incorporated in, and forms part of, the Base Prospectus. The financial statements of AstraZeneca PLC (as a standalone entity) as at and for the year ended 31 December 2025 have not been incorporated in, and do not form part of, the Base Prospectus.

### **General Information**

Save as disclosed in Note 32 (*Subsequent events*) to the audited consolidated financial statements of AstraZeneca PLC as at and for the year ended 31 December 2025, which have been incorporated by reference into the Base Prospectus, since 31 December 2025 there has been no significant change in the financial position or financial performance of the Group. Since 31 December 2025 there has been no material adverse change in the prospects of AstraZeneca PLC. Since 31 December 2025, there has been no material adverse change in the prospects of AstraZeneca Finance.

To the extent that there is any inconsistency between (i) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (ii) any other statement in, or incorporated by reference into, the Base Prospectus, the statements in (i) will prevail.

Any documents themselves incorporated by reference in the document incorporated by reference into the Base Prospectus by this Supplement shall not form part of this Supplement. Any non-incorporated parts of the document referred to herein are either deemed not relevant for an investor or are otherwise covered elsewhere in the Base Prospectus. Unless expressly stated otherwise in this Supplement or the Base Prospectus, the content of websites or URLs referred to in this Supplement, or in the document incorporated by reference by virtue of this Supplement, does not form part of this Supplement or the Base Prospectus and has not been scrutinised or approved by the Financial Conduct Authority.

Save as disclosed in this Supplement there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus since the publication of the Base Prospectus which is capable of affecting the assessment of Notes issued under the Programme since the publication of the Base Prospectus.